China Heparin Industry Report, 2013-2015
  • Oct./2013
  • Hard Copy
  • USD $2,100
  • Pages:84
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: ZYM048
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,100
  • Hard Copy + Single User License
  • USD $2,300
      
Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe. Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012. In 2012, the export volume of heparin APIs in China only registered 103.86 tons (with a year-on-year decline of 1.3%), or about 14.5 trillion units (based on 140IU/mg), addressing 46.5% of global heparin API demand in corresponding period.

Export Volume of Heparin APIs in China and Its Proportion of Global Demand, 2008-2012
肝素英文.jpg

Hepalink, Nanjing King-friend, Dongcheng Biochemicals and Qianhong Bio-pharma are major suppliers of heparin API around the globe. With output and sales volume of heparin API above trillion units in recent years, the four enterprises have been the largest exporters of heparin in China for consecutive years, and shared over 70% of China’s total export of heparin.

Although leading heparin enterprises have had the plans of capacity expansion and heparin industrial chain improvement in previous years, affected by sluggish market demand, enhanced technical standards and other factors, a number of heparin API projects originally planned to start production in 2012 or 2013 were postponed successively, such as the 5T/A project of Hepalink, 2.8T/A project of Dongcheng Bio-chemicals, 4T/A unfractionated heparin sodium and 1.2T/A low-molecular-weight heparin sodium project of Nanjing King-friend. The API project of Qianhong Bio-pharma was completed at the end of 2012, but has not been put into production yet.

Nevertheless, from the perspective of projects proposed and under construction, it is predicted that the newly added capacity of heparin API in China will exceed 23 trillion units by 2015, and the total capacity in China will meet 80% of globe’s total demand.

Along with the increasing of heparin API deliverability, the competitiveness of heparin preparation products in China is also strengthened gradually. Taking the low-molecular-weight heparin calcium market as an example, the market share of GlaxoSmithKline’s Nadroparin in China was 61.0% in 2008, but the figure declined to 52.5% in 2011, and was estimated to decline to 40% or so in 2012. Nevertheless, the low-molecular-weight heparin calcium of Changshan Biochemical has become the first product in China that can compete with the overseas big brands. The revenue of the product only registered RMB86.93 million in 2011, and climbed up to RMB289.6 million in 2012.

China Heparin Industry Report, 2013-2015 mainly consists of the following contents:

20120114.gif Entry barrier, global market supply & demand, competition pattern, forecast, etc. of heparin industry in China;
20120114.gif Development status, market supply & demand, competition pattern, import & export, development prospect, etc. of heparin API industry in China;
20120114.gif Development status, market supply & demand, competition pattern, development prospect, etc. of heparin preparation industry in China;
20120114.gif Operation, heparin business, development prospect, etc. of seven heparin enterprises including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma and Changshan Biochemical.

1. Overview of Heparin Industry 
1.1 Definition and Classification
1.2 Industrial Chain

2. Operating Environment of Heparin Industry in China
2.1 Entry Barrier
2.1.1 Related Policies
2.1.2 Technical Requirements 
2.1.3 Capital Barrier
2.2 Global Market Supply & Demand
2.3 Global Market Competition
2.4 Global Market Forecast

3. Development of Heparin API Industry in China
3.1 Market Status 
3.2 Market Supply & Demand
3.3 Competition Pattern
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Prospect and Forecast

4. Development of Heparin Preparation Industry in China
4.1 Market Size
4.2 Low Molecular Heparin Preparation
4.2.1 Low Molecular Heparin Calcium Preparation
4.2.2 Low Molecular Heparin Sodium Preparation
4.3 Unfractionated Heparin Preparation
4.4 Development Prospect and Forecast

5. Key Heparin Enterprises in China
5.1 Hepalink
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R&D and Investment
5.1.6 Clients and Suppliers
5.1.7 Development Prospect
5.2 Qianhong Bio-pharma
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R&D and Investment
5.2.6 Clients and Suppliers
5.2.7 Heparin Business
5.2.8 Development Prospect
5.3 Dongcheng Biochemicals
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D and Investment
5.3.6 Clients
5.3.7 Heparin Business
5.3.8 Development Prospect
5.4 Changshan Biochemical
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D and Investment
5.4.6 Clients and Suppliers
5.4.7 Development Prospect
5.5 Tianjin Chase Sun
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin 
5.5.5 R&D and Investment
5.5.6 Clients and Suppliers
5.5.7 Heparin Business
5.5.8 Development Prospect
5.6 Nanjing King-friend
5.6.1 Profile
5.6.2 Operation and Development Prospect
5.7 Jiangsu Wanbang
5.7.1 Wanbang Biochemical
5.7.2 Operation and Development Prospect
Application of Heparin
Heparin Industrial Chain
Standard Requirements of Heparin Sodium API and Heparin in China
Market Size of Heparin Preparation Worldwide and YoY Growth, 2006-2012
Performance Comparison Between Low Molecular Weight Heparin Preparation and Unfractionated Heparin Preparation
Market Size of Heparin Preparations Around the Globe by Product, 2010-2012
Regional Distribution of Heparin Preparations Worldwide, 2012
Global Heparin API Demand and YoY Growth, 2007-2012
Major Heparin Preparation Producers Worldwide
Sales of Major Heparin Preparation Brands Globally, 2010-2012
Global Market Size of Heparin Preparations, 2012-2015E
Global Demand for Heparin API, 2011-2014E
Gross Margin of Major Heparin API Producers in China, 2008-2013
Capacity of Heparin Crude Products in China, 2008-2012
Export Average Price of Heparin and Salt in China, 2008-2013
Capacity, Sales Volume and Certification of Major Heparin API Enterprises in China, 2012
Export Volume and Export Value of Heparin and Its Salts in China, 2008-2013
Export Price of Heparin and Its Salts in China, 2008-2013
Top 10 Export Destinations of China’s Heparin and Its Salts by Export Value, 2012-2013
Top 10 Export Enterprises of Heparin and Its Salts in China by Export Value, 2012
Import Volume, Import Value and Unit Price of Heparin and Its Salts in China, 2008-2012
Heparin Sodium API Projects Proposed/Under Construction in China as of Jun. 2013
Market Size of Heparin Preparations in China and YoY Growth, 2007-2012
Market Share of Heparin Preparations in China by Product, 2012
Market Size of Low Molecular Weight Heparin Preparation in China, 2009-2012
Major Heparin Sodium Preparation Enterprises in China and Their Selling Prices, 2008-2011
Market Size of Heparin Preparation in China and YoY Growth, 2012-2015
Assets and Net Income of Hepalink’s Holding Subsidiaries, H1 2013 
Revenue and Profit of Hepalink, 2008-2013
Output, Sales Volume and Inventory of Hepalink’s Heparin Sodium API, 2011-2012
Revenue of Hepalink by Product, 2008-2013
Revenue of Hepalink by Region, 2008-2013
Gross Margin of Hepalink by Product, 2008-2012
R&D Costs and % of Total Revenue of Hepalink, 2009-2013
Hepalink’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Revenue and Operating Income of Hepalink, 2012-2015E
Assets, Revenue and Net Income of Qianhong Bio-pharma’s Subsidiaries (Holding or Joint Stock), H1 2013 
Revenue and Profit of Qianhong Bio-pharma, 2008-2012
Revenue of Qianhong Bio-pharma by Product, 2008-2013
Revenue of Qianhong Bio-pharma by Region, 2008-2013
Gross Margin of Qianhong Bio-pharma by Product, 2008-2013
R&D Costs and % of Total Revenue of Qianhong Bio-pharma, 2009-2013
Capacity of Qianhong Bio-pharma’s Fund-raising Projects, 2011
Progress of Qianhong Bio-pharma’s Projects Proposed/Under Construction as of Jun. 2013
Qianhong Bio-pharma’s Procurement from Top 5 Suppliers and Revenue from Top 5 Clients, 2009-2013
Revenue and Gross Margin of Qianhong Bio-pharma’s Heparin Business, 2008-2013
Revenue and Operating Income of Qianhong Bio-pharma, 2011-2014
Revenue and Profit of Dongcheng Biochemicals, 2008-2013
Operating Revenue of Dongcheng Biochemicals by Product, 2008-2013
Operating Revenue of Dongcheng Biochemicals by Region, 2008-2013
Gross Margin of Dongcheng Biochemicals by Product, 2008-2013
R&D Costs and % of Total Revenue of Dongcheng Biochemicals, 2010-2012
Progress of Dongcheng Biochemicals’ Projects under Research by the End of 2012
Output, Sales Volume and Inventory of Dongcheng Biochemicals’ Heparin Sodium, 2011-2012
Revenue and Gross Margin of Dongcheng Biochemicals’ Heparin Sodium API, 2008-2013
Price of Dongcheng Biochemicals’ Heparin Sodium API, 2009-2011
Revenue Contribution of Top 5 Clients of Dongcheng Biochemicals’ Heparin Sodium API Business, 2009-2011
Revenue and Profit of Dongcheng Biochemicals, 2012-2015E
Revenue and Profit of Changshan Pharmaceutical, 2008-2013
Output, Sales Volume and Inventory of Changshan Pharmaceutical’s Heparin Sodium API and Its Preparations, 2010-2013
Operating Revenue of Changshan Pharmaceutical by Product, 2008-2013
Revenue of Changshan Pharmaceutical by Region, 2008-2013
Gross Margin of Changshan Pharmaceutical by Product, 2008-2013
R&D Costs and % of Total Revenue of Changshan Pharmaceutical, 2009-2013
Progress of Changshan Pharmaceutical’s Products under Research as of Jun. 2013
Name List and Revenue Contribution of Changshan Pharmaceutical’s Top 5 Clients, 2012
Name List and Revenue Contribution of Changshan Pharmaceutical’s Top 5 Clients, H1 2013
Name List and Procurement of Changshan Pharmaceutical’s Top 5 Suppliers, H1 2013
Revenue and Net Income of Changshan Pharmaceutical, 2012-2015E
Output, Sales Volume and Inventory of Chase Sun Pharmaceutical’s Finished Drug Products, 2011-2012
Revenue and Profit of Chase Sun Pharmaceutical, 2008-2013
Operating Revenue of Chase Sun Pharmaceutical by Product, 2008-2013
Revenue of Chase Sun Pharmaceutical by Region, 2008-2013
Gross Margin of Chase Sun Pharmaceutical by Product, 2008-2013
R&D Costs and % of Total Revenue of Chase Sun Pharmaceutical, 2009-2012
Name List and Revenue Contribution of Chase Sun Pharmaceutical’s Top 5 Clients, 2011
Name List and Procurement of Chase Sun Pharmaceutical’s Top 5 Suppliers, 2011
Revenue and Gross Margin of Chase Sun Pharmaceutical’s Heparin Business, 2008-2013
Revenue and Net Income of Chase Sun Pharmaceutical, 2012-2015E
Existing and Fund-raised Heparin API and Preparation Capacities of Nanjing King-friend
Assets, Revenue and Profit Margin of Jiangsu Wanbang, 2012-2013

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号